文献速递胸部肿瘤

FISH检测EGFR基因拷贝数或可预测肺鳞癌奈妥木单抗疗效:SQUIRE研究分析

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
PubMed 文献 · J Thorac Oncol · 2017-11-20

该研究基于SQUIRE试验中557例肺鳞癌患者的标本,用FISH和Colorado评分分析EGFR基因拷贝数增益与奈妥木单抗疗效的关系。结果显示高多体和基因扩增患者从奈妥木单抗联合化疗中获益不同,提示FISH检测的EGFR拷贝数增益可能作为预测生物标志物。

要点

  • 557例可评估患者中208例(37.3%)为FISH阳性,包括高多体167例(30.0%)和基因扩增41例(7.4%)。
  • 高多体患者加用奈妥木单抗显著改善PFS(6.08 vs 5.13个月,p=0.044),OS无统计学显著改善(12.6 vs 9.5个月,p=0.133)。
  • 基因扩增患者加用奈妥木单抗OS显著改善(14.8 vs 7.6个月,p=0.033),PFS无显著改善(7.4 vs 5.6个月,p=0.334)。

核心结论

  • FISH检测的EGFR拷贝数增益可能作为肺鳞癌奈妥木单抗的预测生物标志物,需进一步前瞻性研究验证。

研究设计与样本

  • SQUIRE试验的事后分析,对557例肺鳞癌患者标本进行中心实验室FISH检测,采用Colorado EGFR评分标准评估拷贝数增益与临床结局的相关性。

主要发现

  • 557例中FISH阳性208例(37.3%),其中高多体167例(30.0%),基因扩增41例(7.4%)。
  • 高多体患者加用奈妥木单抗后PFS显著延长(6.08 vs 5.13个月,p=0.044),OS无显著差异(12.6 vs 9.5个月,p=0.133)。
  • 基因扩增患者加用奈妥木单抗后OS显著延长(14.8 vs 7.6个月,p=0.033),PFS无显著差异(7.4 vs 5.6个月,p=0.334)。

关键数值与推荐

  • FISH阳性定义为高多体或基因扩增,采用Colorado EGFR评分标准判读。
  • 高多体患者加用奈妥木单抗PFS获益显著(p=0.044),基因扩增患者OS获益显著(p=0.033)。

临床怎么用

  • 对于肺鳞癌患者,可考虑通过FISH检测EGFR拷贝数增益(高多体或基因扩增)来辅助筛选可能从奈妥木单抗联合化疗中获益的人群。

局限性

  • 仅为SQUIRE试验的事后探索性分析,样本量有限(557例可评估),结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Necitumumab is a monoclonal antibody targeting EGFR. In the SQUIRE trial, the addition of necitumumab to chemotherapy for squamous cell lung cancer significantly improved overall survival (OS) (hazard ratio [HR] = 0.84); in a post hoc analysis, EGFR copy number gain determined by fluorescence in situ hybridization (FISH) showed a trend toward improved OS (HR = 0.70) and progression-free survival (PFS) (HR = 0.71) with the addition of necitumumab. We present the analysis of granular EGFR FISH data from SQUIRE to examine the potential predictive role of high polysomy and gene amplification, as both were included in the FISH-positive category. METHODS: Available specimens from SQUIRE underwent FISH analysis in a central laboratory, and each sample was evaluated by using the Colorado EGFR scoring criteria. The correlation of granular FISH parameters with clinical outcomes was assessed. RESULTS: Samples were available for 557 of 1093 patients; 208 patients (37.3%) were FISH-positive, including 167 (30.0%) with high polysomy and 41 (7.4%) with gene amplification. In patients with high polysomy, the addition of necitumumab resulted in a statistically significant increase in PFS (6.08 versus 5.13 months [p = 0.044]) and nonstatistically significant increase in OS (12.6 versus 9.5 months [p = 0.133]); among patients with gene amplification, the addition of necitumumab did not significantly improve PFS (7.4 versus 5.6 months; [p = 0.334]) but did improve OS (14.8 versus 7.6 months; [p = 0.033]). CONCLUSIONS: EGFR copy number gain by FISH might have a role as a predictive biomarker for necitumumab in squamous cell lung cancer. In our opinion, these data encourage further studies to prospectively evaluate this potential biomarker.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Genova C, Socinski MA, Hozak RR, et al. EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol. 2017. PMID: 29158193. doi:10.1016/j.jtho.2017.11.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。